ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Science

Fujifilm to partner with Takeda on regenerative heart medicine

Clinical trials scheduled for drug that uses induced pluripotent stem cells

TOKYO -- Fujifilm will partner with Takeda Pharmaceutical to develop and sell a regenerative medicine product for heart patients, the company announced Thursday.

The deal combines Fujifilm's manufacturing expertise with Takeda's experience in clinical tests and pharmaceutical sales. The product, which is being developed by Fujifilm's U.S. subsidiary Cellular Dynamics International, uses induced pluripotent stem cells.

The companies expect the product, which helps restore the heart muscle in patients with grave heart failure symptoms, to begin clinical tests as early as 2019. It is currently being tested on lab animals.

The deal represents the first tie-up for the two companies.

Fujifilm acquired Wako Pure Chemical Industries, a laboratory chemicals manufacturer, from Takeda in 2017.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media